Recurrent platinum resistant ovarian cancer

Author: asjl

August undefined, 2024

WebA dose-escalation phase 1b study of alpelisib (a PI3K inhibitor) and olaparib demonstrated that among 28 women with epithelial ovarian cancer, 82% of whom had platinum-resistant disease, 36% had a partial response (median 5.5 months) and 50% had stable disease. 43 It should be noted that this was not the primary endpoint of the study. However ... Web21 hours ago · The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted a fast track designation by the FDA. The multicenter, single-agent, open-label, phase 1b trial will be conducted in 25-30 states in the United States, United Kingdom, and Europe, and plans to enroll 2 cohorts of up to approximately 25 patients each.

Phase 3 Trial Further Examines Maintenance Mirvetuximab …

WebOncolytic virotherapy is a multifaceted immunotherapy that is emerging as a significant contribution to the treatment of platinum-resistant ovarian cancer. Oncolytic viruses are nonpathogenic viral strains that specifically infect cancer cells, triggering their demise [54]. WebFeb 23, 2024 · The problem with platinum resistant recurring ovarian cancer is that it has a poor prognosis. It also has a short OS (less than 12 months). Treatment options for these cases are limited and do not prolong survival. Treatments for Platinum-resistant Ovarian Cancer The commonly used treatments are PLD, topotecan, paclitaxel, and gemcitabine. atakth

Treatment options for recurrent platinum-resistant …

WebFeb 2, 2024 · Monk: Recurrent ovarian cancer remains a high unmet need because [essentially] every patient who gets it dies. It is a terminal condition. We have historically bifurcated into 2 groups, platinum-resistant [disease] and platinum-sensitive [disease, and we’ve] evolved that terminology into those who are eligible for platinum and those who … WebJul 30, 2011 · Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge. … WebThe therapeutic landscape of ovarian cancer is also rapidly evolving, and alternative therapies are becoming available for the recurrent platinum-resistant disease. This … ataktista

Platinum-Resistant Ovarian Cancer - an overview - ScienceDirect

Relacorilant Plus Nab-Paclitaxel May Improve Over ... - Cancer …

WebApr 10, 2024 · The phase 1b/2, multicenter DeCidE1 trial (NCT02785250) was designed to evaluate MVP-S combined with intermittent low dose of cyclophosphamide in patients … WebApr 11, 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be … asian supermarket frankfurtWebApr 1, 2024 · The primary objective of this study is to evaluate the safety and tolerability of PHI-101 in platinum-resistant recurrent ovarian cancer. Methods: Chk2 inhibitor for … asian supermarket fuengirola

"WebTherapy options for patients with recurrent, platinum-resistant ovarian cancer are limited. Cortisol contributes to chemotherapy resistance, one driver of poor outcomes, by suppressing apoptotic pathways used by cytotoxic agents. " - Recurrent platinum resistant ovarian cancer

Recurrent platinum resistant ovarian cancer

What to Know About Ovarian Cancer Recurrence - WebMD

WebMay 28, 2024 · If you previously received platinum-based chemotherapy to treat the cancer and your last dose of chemo was administered within the past 6 months, the cancer will … WebMar 14, 2024 · Prognosis for patients with ovarian cancer is influenced by multiple factors. Multivariate analyses suggest that the most important favorable prognostic factors include the following: [ 43 - 47] Younger age. …

Did you know?

WebJan 23, 2024 · Although up to 25% of women with ovarian cancer have innately (or primary) platinum-refractory disease, most patients are sensitive to front-line platinum therapy but will unfortunately develop recurrence and acquire progressive resistance over time. … WebApr 1, 2024 · The primary objective of this study is to evaluate the safety and tolerability of PHI-101 in platinum-resistant recurrent ovarian cancer. Methods: Chk2 inhibitor for Recurrent EpitheliAl periToneal, fallopIan, or oVarian cancEr (CREATIVE) trial is a prospective, multi-centre, phase IA dose-escalation study. Six cohorts of dose levels are ...

WebSep 16, 2024 · Platinum-resistant recurrent ovarian cancer (PROC): the patient was diagnosed with platinum-resistant recurrence for the first time. PROC refers to the … WebPurpose: To evaluate the effectiveness of bevacizumab with single-agent chemotherapy for platinum-resistant ovarian cancer in a real-world setting. Patients and methods: We enrolled recurrent platinum-resistant ovarian cancer patients from 27 institutions. All had received bevacizumab with single-agent chemotherapy (weekly paclitaxel, pegylated liposomal …

WebApr 14, 2024 · PURPOSE Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven efficacy in treatment of BReast CAncer (BRCA) gene mutation-positive platinum-sensitive ovarian cancers. There is paucity of data for their role in platinum-resistant ovarian cancer (PROC). We report here retrospective analysis of outcome of PARPi treatment in a group … WebApr 8, 2024 · In November 2014, the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) for platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or peritoneal cancers in patients who received no more than two prior chemotherapy regimens. It is indicated in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan.

WebThe AURELIA trial was a Phase III randomized, double-blind trial on 361 patients with recurrent platinum-resistant epithelial ovarian cancer, peritoneal cancer, and carcinoma of the fallopian tube, whose disease had progressed ≤6 months after receiving four cycles or more of treatment with platinum-based chemotherapy . 18 Patients were ...

Web“Platinum resistant” ovarian cancer was historically defined as disease recurrence within 6months of completion of first-line platinum-based chemotherapy, although this is now … ataktisk gangeWebApr 10, 2024 · Ovarian cancer is the most fatal gynecologic malignancy, as it is commonly diagnosed at an advanced stage. ... In platinum-resistant disease, recurrence happens … asian supermarket fyshwickWebSep 17, 2024 · “Women with recurrent platinum-resistant ovarian cancer have few therapeutic options,” said William Guyer, PharmD, Corcept’s Chief Development Officer. “The results presented at ESMO today... atakul dişWebOct 24, 2007 · Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to … ataktoWebOf the 38 women enrolled, 18 had platinum-resistant with an ORR of 16.7% (95% CI 3.6–41.4%) compared to an ORR of 40% in platinum-sensitive cohort. Median PFSPFS by RECIST was 7.7 months in PROC vs 12.1 months in platinum-sensitive patients. Nine participants (23.7%) experienced a grade 3 or higher TRAEs. 37. atakto kontaktWebThe RR of these agents is in the 10–15% range and overall survival of platinum-resistance ovarian cancer patients is around 12 months. 18 PARP inhibitors as maintenance therapy can improve the prognosis of patients, but the efficacy of monotherapy for platinum-resistance ovarian cancer is still limited. 8,9 It is urgent to explore new ... asian supermarket fresnoWebSep 17, 2024 · In their study, the investigators randomised women with recurrent platinum-resistant or refractory high-grade serous or endometroid epithelial ovarian, primary … asian supermarket fremantle